Literature DB >> 7889545

Identification of prodrug, active drug, and metabolites in an ADEPT clinical study.

C J Springer1, G K Poon, S K Sharma, K D Bagshawe.   

Abstract

Antibody-directed enzyme prodrug therapy (ADEPT) involves two phases. The first is an antibody-enzyme conjugate that localizes to tumor. The second phase is a prodrug that is administered when the enzyme-conjugate has cleared from blood and other nontumor tissues. In the pilot-scale clinical trial, the prodrug has been measured--in the plasma of patients, by liquid chromatography (HPLC) and by liquid chromatography-mass spectrometry (LC-MS). Active drug has been detected and metabolites identified. An indirect measurement of enzyme-conjugate in the plasma of patients has also been developed.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7889545     DOI： 10.1007/bf03033864

Source DB:  PubMed          Journal:  Cell Biophys        ISSN： 0163-4992


  12 in total

1.  Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.

Authors:  C J Springer; P Antoniw; K D Bagshawe; F Searle; G M Bisset; M Jarman
Journal:  J Med Chem       Date:  1990-02       Impact factor: 7.446

2.  Carboxypeptidase-mediated release of methotrexate from methotrexate alpha-peptides.

Authors:  U Kuefner; U Lohrmann; Y D Montejano; K S Vitols; F M Huennekens
Journal:  Biochemistry       Date:  1989-03-07       Impact factor: 3.162

3.  Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method.

Authors:  R F Sherwood; R G Melton; S M Alwan; P Hughes
Journal:  Eur J Biochem       Date:  1985-05-02

4.  Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumor-associated antigens.

Authors:  P H Hand; M Nuti; D Colcher; J Schlom
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

5.  Antibody directed enzyme prodrug therapy (ADEPT): clinical report.

Authors:  K D Bagshawe; S K Sharma; C J Springer; P Antoniw; J A Boden; G T Rogers; P J Burke; R G Melton; R F Sherwood
Journal:  Dis Markers       Date:  1991 May-Aug       Impact factor: 3.434

6.  Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds.

Authors:  C J Springer; K D Bagshawe; S K Sharma; F Searle; J A Boden; P Antoniw; P J Burke; G T Rogers; R F Sherwood; R G Melton
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

7.  Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

Authors:  P D Senter; M G Saulnier; G J Schreiber; D L Hirschberg; J P Brown; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

8.  Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.

Authors:  P Antoniw; C J Springer; K D Bagshawe; F Searle; R G Melton; G T Rogers; P J Burke; R F Sherwood
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

9.  Antibody directed enzymes revive anti-cancer prodrugs concept.

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

10.  A cytotoxic agent can be generated selectively at cancer sites.

Authors:  K D Bagshawe; C J Springer; F Searle; P Antoniw; S K Sharma; R G Melton; R F Sherwood
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640
View more
  6 in total

Review 1.  Targeted prodrug design to optimize drug delivery.

Authors:  H K Han; G L Amidon
Journal:  AAPS PharmSci       Date:  2000

Review 2.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

3.  Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.

Authors:  C J Springer; G K Poon; S K Sharma; K D Bagshawe
Journal:  Cell Biophys       Date:  1994

4.  Prodrugs in Cancer Chemotherapy.

Authors:  Richard J Knox; Tom A Connors
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 5.  Bioengineering strategies for designing targeted cancer therapies.

Authors:  Angela A Alexander-Bryant; Wendy S Vanden Berg-Foels; Xuejun Wen
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

6.  A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.

Authors:  R J Francis; S K Sharma; C Springer; A J Green; L D Hope-Stone; L Sena; J Martin; K L Adamson; A Robbins; L Gumbrell; D O'Malley; E Tsiompanou; H Shahbakhti; S Webley; D Hochhauser; A J Hilson; D Blakey; R H J Begent
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.